Strides Pharma Science Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated annual revenue of Rs. 48,586.83 million and a net profit of Rs. 5,745.20 million for the full year. Demonstrating commitment to shareholder value, the Board of Directors recommended a final dividend of Rs. 5 per equity share, marking a 50% payout for the financial year.
Financial Performance Overview
For the financial year ended March 31, 2026, Strides Pharma reported consolidated revenue from operations of Rs. 48,586.83 million, up from Rs. 45,653.35 million in the previous year. The consolidated net profit for the period stood at Rs. 5,745.20 million, reflecting the company’s operational growth and stable performance across its pharmaceutical business.
Dividend Recommendation
Recognizing the company’s financial health, the Board of Directors has recommended a final dividend of Rs. 5 per equity share of face value Rs. 10 each. This dividend payment, representing a 50% rate, is subject to the approval of shareholders at the company’s upcoming Annual General Meeting. The company will fix a record date in due course to determine eligible shareholders.
Strategic Business Highlights
The consolidated results reflect the company’s continued focus on its single reportable segment, Pharmaceuticals. Throughout the year, the company navigated regulatory requirements and operational challenges, including product recalls and strategic business restructuring. The management remains focused on optimizing resource allocation and maintaining a robust product portfolio, ensuring consistent value creation for stakeholders.
Source: BSE
